For patients with terminal cancer, chemotherapy does not improve quality of life
the ONA take:
Chemotherapy administered to patients with cancer who are near death does not improve quality of life and may even reduce quality of life in those who have good performance status, a recent study published in JAMA Oncology has shown.
For the study, researchers evaluated 312 patients with terminal cancer who were estimated to live no more than 6 months. The majority were receiving chemotherapy. Results showed that patients with a poor performance status who received chemotherapy achieved no improvement in quality of life during their final week prior to death.
Moreover, researchers found that in those with a good performance status, treatment worsened their quality of life compared with patients with a good performance status who were not receiving treatment.
Current American Society of Clinical Oncology (ASCO) guidelines contend that patients with terminal cancer and a good performance status are the most likely to benefit from chemotherapy, but these findings suggest that chemotherapy given to patients at the end of life may be wasteful, unnecessary, and potentially harmful.
Chemotherapy administered to patients with cancer who are near death does not improve quality of life.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|